GUERBET to present its solutions offering at the ECIO in Vienna, Austria from 22 to 25 April 2018
∙ A major event, the ECIO brings together international interventional oncology experts every year
∙ Organization of a symposium “New perspectives in cTACE to improve the treatment of HCC patients” on April 23 from 13:45 to 14:30.
Villepinte (France), April 11, 2018 (6:00 PM CEST) – Guerbet (FR0000032526 GBT), the global specialist in contrast media and solutions for medical imaging, will present its interventional imaging solutions offering at the ECIO (European Conference on Interventional Oncology) in Vienna, Austria from April 22 to 25, 2018.
A major congress organized by the Cardiovascular and Interventional Radiological Society of Europe, the ECIO brings the experts in the field together each year to see the latest innovations and developments in interventional oncology. An interventional imaging specialty, interventional oncology involves the diagnosis and treatment of cancers by mini-invasive procedures guided by imaging.
Guerbet is accelerating its growth in interventional imaging by enriching its portfolio with new solutions to help healthcare professionals improve the quality of treatment in image-guided embolization procedures:
Vectorio®, an innovative mix and injection medical device which standardizes conventional transarterial chemoembolization (cTACE). A unique kit of medical devices resistant to Lipiodol® Ultra Fluid containing syringes, a patented stopcock and sampling systems, Vectorio® obtained CE labelling in August 2017. It is used for mixing and administering Lipiodol® Ultra Fluid with a cancer drug during cTACE procedures in adults suffering from intermediate-stage hepatocellular carcinoma (HCC).
The anti-reflux Accurate1 microcatheter is used for embolization procedures on vascular tumors or aneurysms. This innovative microcatheter enables more embolization microparticles to be administered in the target area, while preventing their reflux upstream to the arteries irrigating the healthy tissues (non-targeted areas to be avoided). It has been authorized for commercialization in the United States by the FDA and is awaiting to be given a CE marking in Europe. This innovation completes a range of standard microcatheters designed and developed to offer interventional radiologists optimized intra-arterial navigation, even in cases of tortuous vascularity and lesions which are difficult to access.
These new devices, along with Guerbet’s flagship product Lipiodol® Ultra Fluid, will be presented in the Guerbet Innovation Lab, enabling interventional radiologists to discover and test them.
At the congress Guerbet will also be organizing a symposium on “New perspectives in cTACE to improve the treatment of HCC patients2”, attended by several international experts on April 23 from 13:45 to 14:30.
Other oral presentations will be made by experts on the Guerbet stand.